Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Wegovy Savings Offer provides similar benefits
A stronger framework could include
Revenue target : OneSource aims to achieve $400 million in annual revenue within the next three years, with semaglutide as a key contributor
Evidence-Based Recommendation : FDA-approved Ozempic remains the gold standard for semaglutide therapy, offering the best combination of proven efficacy, safety oversight, and long-term support for patients with diabetes and weight management goals
This dual action results in significant caloric reduction and subsequent weight loss, with clinical trials demonstrating average weight reductions of 15-21% of body weight over 72 weeks in the SURMOUNT-1 and SURMOUNT-2 trials
US$ 25.25
US$ 28.19
US$ 25.93
US$ 23.99
